Pharmacyclics — Technical Presentation (December 2011)
23 slides from Pharmacyclics's technical presentation, Dec 14, 2011
Slide 1: BTK Inhibitor PCI-32765 in Relapsed/Refractory CLL/SLL: Phase Ib/II Follow-up
The Bruton’ s Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/Il Study ‘Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, T
Slide 2: Bruton's Tyrosine Kinase (BTK)
Bruton’ s Tyrosine Kinase (BTK) Acritical kinase for lymphoma cell survival and proliferation Bell recepror CetePeeeseeer eee enyy = B-cell antigen receptor (BCR) signaling is required for tumor expansion and proliferation Bruton’ s tyrosine kinase (BTK) is an essential element of the BCR signaling
Slide 3: PCI-32765: First-in Class Inhibitor of BTK
PCI-32765: First-in Class Inhibitor of BTK + Forms a specific and irreversible bond with cysteine-481 in BTK ° a@) * Highly potent BTK inhibition at ICyg = 0.5 nM * — Orally administered with once daily dosing resulting in 24-hr target inhibition N * In CLL cells promotes apoptosis, inhibits ERK1/AK
Slide 4: Study Design: PCYC-1102-CA
Study Design: PCYC-1102-CA Multi-cohort study PCI-32765 as a single agent for symptomatic and/or progressive CLL/SLL Two fixed continuous doses 420 mg/day or 840 mg/day until disease progression Objectives: — Response rate, response duration, and PFS — Evaluate safety — Examine pharmacokinetics, pha
Slide 5: PCYC-1102-CA
PCYC-1102-CA Total enrollment 117 patients Dates enrolled 5/20/10 — 7/27/11 High-risk Relapsed/Refractory 420 me/d (n=2! Median follow-up 2.8 months Treatment Naive 2 65 yrs 840 mg/d (n=5) Median follow-up 2.8 months
Slide 6: Relapsed/Refractory cohorts
Relapsed/Refractory 420 mg/d (n=27) Median follow-up 12.6 months PCYC-1102-CA Total enrollment Relapsed/Refractory 117 patients 840 mg/d (n=34) Median follow-up 9.3 months Dates enrolled 5/20/10 — 7/27/11 October 25, 2011 data-cut for presentation «
Slide 7: Patient Eligibility
Patient Eligibility Diagnosis of CLL or SLL and requirement for treatment per NCI or IWCLL guidelines 22 prior therapies including a purine analog Adequate end-organ function ANC 20.75 x 10/L* Platelets > 50 x 10°/L* ALT < 2.5 x ULN Creatinine < 1.5 x ULN No active/uncontrolled infection No malignan
Slide 8: Patient Characteristics
Patient Characteristics #20 mg/d 840 mg/d Total a (N: mall on aa Age, years Median: Range: oe oe Me 80 ie a 270 years, # (%) 9 (33) 10 (29) 19(31) Diagnosis, # (%) CLL: 26 (96) 33 (97) 59(97) SUL: 1(4) 1(3) 2(3) ECOG Performance Status, #(%) 0 11(41) 13 (38) 24 (39) 4/2 16 (59) 21 (62) 37(61) Prior
Slide 9: Patient Characteristics (cont.)
Patient Characteristics (cont.) (N=27) (N=34) (N=61) Bulky Disease, #(%) 25cm 13 (48) 20 (59) 33 (54) 210cm 14) 9 (26) 10 (16) Cytopenia at baseline, # (%) ANC < 1500/uL. 7 (26) 17 (50) 24 (39) HGB < 11g/dL 4 (15) 18 (53) 22 (36) Platelets < 100,000/uL 8 (30) 24 (71) 32 (52) HGB < 11g/dL or PLT < 10
Slide 10: Patient Disposition
Patient Disposition (N=27) (N=34) Number of Patients 27 34 Follow-up Median (months) 12.6 9.3 Range 0.9-15.0 03-111 Patients Still on Study, # (%) 20 (74) 26 (76) Patients Discontinued, # (%) 7 (26) 8 (24) Primary Reasons for Discontinuation, # (%) Disease Progression 2(7) 1(3) Death? 1(4) 2(6) Adve
Slide 11: Common AEs (All Grades)
Common AEs (All Grades)—Events occurring in > 15% of Patients (regardless of attribution) (n=61) Diarchea | Cough Fatigue TT RT Muscle spasms TCT Nasco TT Edema Peripheral | Pyrexia Artheagia aay Contusion 0% 10% 20% 30% 40% 50% lm Grade1 mmm Grade2 mmm Grade3 mmm Grade4
Slide 12: Grade 3/4 Infectious and Hematologic Toxicity
Grade 3/4 Infectious and Hematologic Toxicity (regardless of attribution) Grade 3/4 Hematology 420 mg/d 840 mg/d toxicity * (n=27) (n=34) Grade 3 Grade 4 Grade 3 Grade 4 Neutropenia 4% 4% 12% 9% Anemia 7% 0% 9% 3% Thrombocytopenia 0% 1% 9% ~—-0% 420 mg/d 7) Grade 3 Grade 4 Grade 3 Grade 4 Patients w
Slide 13: % Change from Baseline SPD
% Change from Baseline SPD Maximum Change in Tumor Burden 50 25 m= 420 mg/d mms 840 mg/d -100 *Patient developed progressive disease, but did not have tumor measurements available Limited to patients with measurable disease at baseline (n=55)
Slide 14: Pattern of Response
Pattern of Response Blood Lymphocytes vs Lymph Nodes — SPD — ALC | { | | i / Mean Percent Change from Baseline Month SPD ~ sum of products of lymph node dimension
Slide 15: Response Criteria
Response Criteria * NHLIWG criteria’ were applied to SLL cases * The 2008 IWCLL criteria? were applied to CLL cases with the following modifications: — Treatment-related lymphocytosis, in the absence of other parameters meeting the criteria for PD, was not considered PD. — “Nodal” response describes
Slide 16: Best Response
Best Response / (N=27) (N=34) 1) # (%) # (%) | #(%) | CR 1(4) 0 (0) 1(2) PR 17 (63) 23 (68) 40 (66) a Nodal 6 (22) 8 (24) 14 (23) i 1(4) 1(3) 2(3) PD 1(4) 0 (0) 1(2) | NE 1(4) 2 (6) 3 (5) "Per IWCLL 2008 criteria
Slide 17: Cumulative Best Response 420 mg/d cohort
Cumulative Best Response 420 mg/d cohort (n=27) 80% 67% wa 59% 409 | 56% 56% 48% MN% 34%| 33% i ] I ' 1 0% 20% Oe 2 Cycle5 Cycles Cycle 11 fettiatiee Response Rate % R & m CR miPR_ Nodal Response
Slide 18: Best Response by Risk Features
Best Response by Risk Features All Patients 270 years age Bulky disease 2 5 cm 2/38 | Bulky disease > 10 cm 7/10 70 | Hb <1 g/dl or PLT <100K/ul at screening rr igVH unmutated 31/42 74 | Del 17p 13/20 6 Del iiq 16/22 B B2 Microglobulin > 3mg/L 19/29 66 | Purine Analog Refractory 17/28 61 (< 12 mos f
Slide 19: Sustained Improvement in Blood Counts
Sustained Improvement’ in Blood Counts in Patients with Pre-treatment Cytopenias 25% Total Platelet: atelets ed 70% 18/31 58% ra! 7 65% 14/21 67% 71% ay Total 9/7 53% 14/24 58% 0% 20% 40% 60% 80% 420 mg/d (n=27) 840 mg/d (n=34) “Sustained improvement is defined as improvement in oytopenia by >50%, o
Slide 20: PFS Probability
PFS Probability Progression-free Survival 104 094 084 074 064 05-4 o44 034 024 014 00+ OAc ea — 420 mg/d (n=27) —— 240 mg/d (n=34) ° vn T T T T T T T 6 8 10 12 14 16 Months on Study
Slide 21: PFS Probability by 17p Del Status
PFS Probability Progression-free Survival by 17p Del Status 104 094 084 o74 06-4 054 o44 034 024 0414 004 — 17p Del No (n=88) — 7p Del Yes (n=20) Months on Study
Slide 22: Conclusions
Conclusions PCI-32765 a first-in-class, selective, covalent irreversible inhibitor of BTK administered as a single- agent to patients with relapsed or refractory CLL: * Resulted in a high ORR (67%) with 12-month PFS of 86% * Clinical activity is independent of poor-risk clinical or genetic features
Slide 23: Acknowledgement
Acknowledgement Thank you to all the patients who participated in the study, their families, all the clinical institutes and research staff, and Pharmacyclics.
Pharmacyclics — Technical Presentation (December 2011) on 6ix